Literature DB >> 24246428

Single-reagent one-step procedures for the purification of ovine IgG, F(ab')2 and Fab antivenoms by caprylic acid.

Ibrahim Al-Abdulla1, Nicholas R Casewell2, John Landon1.   

Abstract

Antivenoms are typically produced in horses or sheep and often purified using salt precipitation of immunoglobulins or F(ab')2 fragments. Caprylic (octanoic) acid fractionation of antiserum has the advantage of not precipitating the desired antibodies, thereby avoiding potential degradation that can lead to the formation of aggregates, which may be the cause of some adverse reactions to antivenoms. Here we report that when optimising the purification of immunoglobulins from ovine antiserum raised against snake venom, caprylic acid was found to have no effect on the activity of the enzymes pepsin and papain, which are employed in antivenom manufacturing to digest immunoglobulins to obtain F(ab')2 and Fab fragments, respectively. A "single-reagent" method was developed for the production of F(ab')2 antivenom whereby whole ovine antiserum was mixed with both caprylic acid and pepsin and incubated for 4h at 37°C. For ovine Fab antivenom production from whole antiserum, the "single reagent" comprised of caprylic acid, papain and l-cysteine; after incubation at 37°C for 18-20h, iodoacetamide was added to stop the reaction. Caprylic acid facilitated the precipitation of albumin, resulting in a reduced protein load presented to the digestion enzymes, culminating in substantial reductions in processing time. The ovine IgG, F(ab')2 and Fab products obtained using these novel caprylic acid methods were comparable in terms of yield, purity and specific activity to those obtained by multi-step conventional salt fractionation with sodium sulphate.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody purification; F(ab′)(2); Fab; IgG; Snake antivenom; Venom

Mesh:

Substances:

Year:  2013        PMID: 24246428     DOI: 10.1016/j.jim.2013.11.001

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Streamlined downstream process for efficient and sustainable (Fab')2 antivenom preparation.

Authors:  Tihana Kurtović; Marija Brgles; Maja Lang Balija; Stephanie Steinberger; Dora Sviben; Martina Marchetti-Deschmann; Beata Halassy
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2020-07-27

2.  Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome.

Authors:  Ching-Li Tseng; Zhi-Yu Chen; Ting-Yi Renn; Shun-Hung Hsiao; Thierry Burnouf
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

3.  Refinement strategy for antivenom preparation of high yield and quality.

Authors:  Tihana Kurtović; Maja Lang Balija; Marija Brgles; Dora Sviben; Monika Tunjić; Hrvoje Cajner; Martina Marchetti-Deschmann; Günter Allmaier; Beata Halassy
Journal:  PLoS Negl Trop Dis       Date:  2019-06-17

4.  Preparation and Neutralization Efficacy of Novel Jellyfish Antivenoms against Cyanea nozakii Toxins.

Authors:  Rongfeng Li; Huahua Yu; Aoyu Li; Chunlin Yu; Pengcheng Li
Journal:  Toxins (Basel)       Date:  2021-02-21       Impact factor: 4.546

5.  Anti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia.

Authors:  Ying-Jan Weng; Anne Husebekk; Björn Skogen; Mette Kjaer; Liang-Tzung Lin; Thierry Burnouf
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

6.  Research into the Causes of Venom-Induced Mortality and Morbidity Identifies New Therapeutic Opportunities.

Authors:  Kesturu S Girish; Gajanan D Katkar; Robert A Harrison; Kempaiah Kemparaju
Journal:  Am J Trop Med Hyg       Date:  2019-05       Impact factor: 2.345

7.  The Immunogenicity of the C Fragment of Tetanus Neurotoxin in Production of Tetanus Antitoxin.

Authors:  Rui Yu; Chong Ji; Junjie Xu; Denghai Wang; Ting Fang; Yue Jing; Clifton Kwang-Fu Shen; Wei Chen
Journal:  Biomed Res Int       Date:  2018-12-31       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.